Phase II Clinical Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B-cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma (Multicenter, Open-label).
Phase of Trial: Phase II
Latest Information Update: 01 Apr 2017
At a glance
- Drugs Bendamustine (Primary) ; Rituximab
- Indications B-cell lymphoma; Mantle-cell lymphoma
- Focus Therapeutic Use
- Sponsors SymBio Pharmaceuticals
- 01 Apr 2017 Results published in the International Journal of Hematology
- 07 Jun 2016 Results assessing efficacy and safety, presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 10 Feb 2015 According to a media release, SymBio Pharmaceuticals is planning to file the sNDA in Japan, following the decision for marketing approval by Federal Institute for Drugs and Medical Devices in Europe.